Even with a 3-5% cost to convert [stablecoin] USDT into equities, the potential upside of …
SAN FRANCISCO, Oct. 29, 2024 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN), the nation’s leading provider …
One trader said ether’s sell-off on positive news is typical “buy the rumors, sell the …
by Linh Nguyen
Tigran Gambaryan was remanded pending trial, reports say. Binance executive Tigran Gambaryan, who was detained …
by Linh Nguyen
Nowadays, it’s hardly surprising to see Play-to-Earn (P2E) mechanics in new projects entering the market.
Nowadays, it’s hardly surprising to see Play-to-Earn (P2E) mechanics in new projects entering the market.
Latest
-
-
Stablecoin margined futures on DOGE have spiked, with DOGE denominated bets rising 33% since Sunday. …
-
BusinessGlobeNewswire
Acadia Healthcare (ACHC) Faces Class Action Lawsuit Over Patient Detention Practices – Hagens Berman
ACHC Investors with Losses Encouraged to Contact the FirmSAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) …
-
RANCHO CORDOVA, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) — Five Star Bancorp (Nasdaq: FSBC) (“Five Star” …
-
BusinessGlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Elanco Animal Health Incorporated Investors to Secure Counsel Before Important Deadline in Securities Class Action – ELAN
NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights …
-
BusinessGlobeNewswire
FSLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into First Solar, Inc. and Encourages Investors to Contact the Firm
NEW YORK, Oct. 27, 2024 (GLOBE NEWSWIRE) — Attorney Advertising — Bronstein, Gewirtz & Grossman, …
-
BusinessGlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Acadia Healthcare Company, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ACHC
NEW YORK, Oct. 26, 2024 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights …
-
BusinessGlobeNewswire
Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria
First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled …